Rigel in-licensed olutasidenib, an oral, mutant isocitrate dehydrogenase-1 (mIDH1) inhibitor, with exclusive, worldwide rights to develop, manufacture, and commercialize in all indications, including relapsed/refractory acute myeloid leukemia and other malignancies.

Under the terms of the agreement, Forma will receive an upfront payment and is eligible to receive additional near-term regulatory, approval, and first commercial sale milestones.  In addition, Forma is eligible to receive additional development and commercial milestones, and tiered royalties.

Rigel is responsible for the commercialization of olutasidenib in the U.S., and intends to work with potential partners to further develop and commercialize olutasidenib outside the U.S.